Journal
CLINICAL INFECTIOUS DISEASES
Volume 68, Issue 8, Pages 1255-1264Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciy706
Keywords
cytomegalovirus; foscarnet; ganciclovir; maribavir; transplantation
Categories
Funding
- ViroPharma/Shire Development, LLC
- Shire International GmbH
Ask authors/readers for more resources
Background. Cytomegalovirus (CMV) infections that are refractory or resistant (RR) to available antivirals ([val]ganciclovir, foscarnet, cidofovir) are associated with higher mortality in transplant patients. Maribavir is active against RR CMV strains. Methods. Hematopoietic-cell or solid-organ transplant recipients >= 12 years old with RR CMV infections and plasma CMV deoxyribonucleic acid (DNA) >= 1000 copies/mL were randomized (1: 1: 1) to twice-daily dose-blinded maribavir 400, 800, or 1200 mg for up to 24 weeks. The primary efficacy endpoint was the proportion of patients with confirmed undetectable plasma CMV DNA within 6 weeks of treatment. Safety analyses included the frequency and severity of treatment-emergent adverse events (TEAEs). Results. From July 2012 to December 2014, 120 patients were randomized and treated (40 per dose group): 80/120 (67%) patients achieved undetectable CMV DNA within 6 weeks of treatment (95% confidence interval, 57-75%), with rates of 70%, 63%, and 68%, respectively, for maribavir 400, 800, and 1200 mg twice daily. Recurrent on-treatment CMV infections occurred in 25 patients; 13 developed mutations conferring maribavir resistance. Maribavir was discontinued due to adverse events in 41/120 (34%) patients, and 17/41 discontinued due to CMV infections. During the study, 32 (27%) patients died, 4 due to CMV disease. Dysgeusia was the most common TEAE (78/120; 65%) and led to maribavir discontinuation in 1 patient. Absolute neutrophil counts <1000/mu L were noted in 12/106 (11%) evaluable patients, with rates similar across doses. Conclusions. Maribavir >= 400 mg twice daily was active against RR CMV infections in transplant recipients; no new safety signals were identified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available